Two-Year arthritis drug study shows promise for symptom control
NCT ID NCT03106051
Summary
This study followed over 500 adults with active psoriatic arthritis for about two years to see how well the drug apremilast (Otezla®) worked in everyday medical practice. Researchers tracked changes in joint pain, swelling, skin symptoms, and overall quality of life. The goal was to gather long-term safety and effectiveness data for this already-approved medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum Stephansplatz
Hamburg, 20354, Germany
-
Rheumatology at Struenseehaus
Altona, Hamburg, 22767, Germany
Conditions
Explore the condition pages connected to this study.